Betoptic: Expert Ophthalmic Solution for Glaucoma Control
| Product dosage: 5ml | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 3 | $13.39 | $40.17 (0%) | 🛒 Add to cart |
| 4 | $12.05 | $53.56 $48.21 (10%) | 🛒 Add to cart |
| 5 | $11.05 | $66.96 $55.24 (18%) | 🛒 Add to cart |
| 6 | $10.88 | $80.35 $65.28 (19%) | 🛒 Add to cart |
| 7 | $10.47 | $93.74 $73.32 (22%) | 🛒 Add to cart |
| 8 | $10.29 | $107.13 $82.36 (23%) | 🛒 Add to cart |
| 9 | $10.04 | $120.52 $90.39 (25%) | 🛒 Add to cart |
| 10 | $9.84
Best per bottle | $133.91 $98.43 (26%) | 🛒 Add to cart |
Synonyms | |||
Betoptic (betaxolol hydrochloride ophthalmic solution) is a trusted, prescription-only beta-blocker eye drop specifically formulated to manage elevated intraocular pressure. As a cornerstone in glaucoma therapy, it offers targeted action to help prevent optic nerve damage and preserve vision. Its selective mechanism provides effective pressure reduction with a favorable systemic safety profile, making it a first-line choice for ophthalmologists worldwide. This card provides comprehensive, expert-level information for healthcare professionals and informed patients.
Features
- Active ingredient: Betaxolol hydrochloride 0.5%
- Pharmaceutical class: Cardioselective beta-1 adrenergic receptor antagonist
- Formulation: Sterile, isotonic, buffered ophthalmic solution
- Preservative: Benzalkonium chloride 0.01%
- pH: Approximately 6.0–7.4
- Osmolality: 260–330 mOsm/kg
- Available in: 2.5 mL, 5 mL, and 10 mL dropper bottles
Benefits
- Effectively lowers intraocular pressure (IOP) by reducing aqueous humor production
- Cardioselective action minimizes pulmonary and vascular side effects compared to non-selective beta-blockers
- Helps slow progression of glaucoma and reduces risk of vision field loss
- Convenient twice-daily dosing supports patient adherence
- Well-tolerated local ocular profile with low incidence of stinging upon instillation
- May be used as monotherapy or in combination with other IOP-lowering agents
Common use
Betoptic is primarily indicated for the chronic management of open-angle glaucoma and ocular hypertension. It is suitable for patients requiring long-term IOP control and may be prescribed when other beta-blockers are contraindicated due to respiratory concerns. It is often used as initial monotherapy or as part of a multi-drug regimen when target pressure is not achieved with a single agent.
Dosage and direction
The usual dose is one drop of Betoptic 0.5% in the affected eye(s) twice daily. If using with other topical ophthalmic products, administer at least 5 minutes apart. To administer: wash hands, tilt head back, pull down lower eyelid to form a pouch, instill one drop, close eye gently, and apply light pressure to the lacrimal sac for 1–2 minutes to minimize systemic absorption. Do not touch dropper tip to any surface to avoid contamination.
Precautions
- Use with caution in patients with history of cardiac failure, sinus bradycardia, or cardiogenic shock
- Monitor patients with diabetes carefully as betaxolol may mask hypoglycemic symptoms
- May cause blurred vision temporarily after instillation; avoid driving or operating machinery until vision clears
- Not recommended in patients wearing soft contact lenses; remove lenses before administration and wait 15 minutes before reinsertion
- Discontinue gradually if long-term therapy is to be stopped to avoid rebound hypertension
- Pregnancy Category C: use only if potential benefit justifies potential risk to fetus
Contraindications
- Hypersensitivity to betaxolol or any component of the formulation
- Sinus bradycardia
- Greater than first-degree atrioventricular block
- Cardiogenic shock
- Patients with overt cardiac failure
- History of bronchospasm or severe chronic obstructive pulmonary disease (though relative due to cardioselectivity)
Possible side effect
Common: Transient ocular burning/stinging (∼25%), blurred vision, foreign body sensation, itching, tearing. Less common: Bradycardia, hypotension, dizziness, insomnia, depression, bronchospasm (rare). Ocular: Epiphora, photophobia, keratitis, ptosis. Systemic effects are uncommon but may include dyspnea, headache, and taste perversion.
Drug interaction
- Additive effects with oral beta-blockers, calcium channel blockers, digoxin
- Reduced efficacy with sympathomimetics (e.g., epinephrine)
- Enhanced hypoglycemic effect with insulin and oral antidiabetics
- Possible potentiation of myocardial depression with anesthetics
- Concurrent use with quinidine may increase betaxolol concentrations
Missed dose
If a dose is missed, administer as soon as remembered unless it is nearly time for the next dose. Do not double the dose. Maintain the regular dosing schedule. Consistent daily use is important for optimal IOP control.
Overdose
Ocular overdose may cause increased local side effects. Systemic overdose (though rare from ocular administration) may present as bradycardia, hypotension, bronchospasm, acute cardiac failure. Management: supportive care, atropine for bradycardia, beta-agonists for bronchospasm, cardiac monitoring. Dialysis is not effective.
Storage
Store at controlled room temperature (15°–30°C). Protect from light. Keep bottle tightly closed when not in use. Discard 28 days after first opening. Do not freeze. Keep out of reach of children.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions. Dosage and suitability depend on individual patient factors. Full prescribing information should be reviewed before use.
Reviews
Clinical studies demonstrate Betoptic reduces IOP by 20–25% with twice-daily dosing. Ophthalmologists appreciate its cardioselectivity and reliable efficacy. Patients report good tolerability, though some note mild transient stinging. Long-term users confirm stable pressure control and convenience of b.i.d. regimen. Combination therapy with prostaglandin analogs shows synergistic effects.